https://www.selleckchem.com/pr....oducts/eribulin-mesy
The drug inhibits the in vivo growth of multiple KRASG12C -mutant cell line xenografts, causes tumor regression in patient-derived xenograft models, and shows striking responses in combination with other agents. It has also produced objective responses in patients with mutant-specific lung and colorectal cancer. In this review, we discuss the history of RAS drug targeting efforts, the discovery of MRTX849, and how this drug provides an exciting and long-awaited opportunity to selectively target mutant KRAS in patients. T
Like
Comment
Share
